The most potent antagonists emerging from this study, compounds 24a and 25b, were selected to study for the first time the effect of pharmacological blockade of FPR1 in AGS and NCl–N87 cells, two cell models of GC. The gene discussed is FPR1; the disease is gastric cancer.